Abstract
The diagnosis of recurrent ovarian carcinoma is usually determined at surgical re-exploration since the main non-invasive diagnostic tests have low accuracy. It would be desirable to have a high accuracy non-invasive diagnostic procedure. With this aim, we have assessed the utility of three-step immunoscintigraphy. Thirty patients were intravenously injected with biotinylated monoclonal antibodies MOv18 and B72.3, followed by avidin–streptavidin injection and finally by 111In-biotin. Tumour recurrences were imaged 2 h post radioactivity injection. All patients underwent surgical re-exploration 3–4 days after immunoscintigraphy; the presence of tumour in the area of immunoscintigraphic uptake was evaluated in the biopsied material. Twenty-one patients studied were true-positive, five were true-negative, four were false-positive and none was false-negative. The diagnostic accuracy, positive predictive value and negative predictive value were 87%, 84% and 100% respectively. If these findings are confirmed in a larger number of patients, we expect immunoscintigraphy to be introduced as a cost-effective procedure in the follow-up of patients who have received surgery for ovarian carcinoma, since it promises to reliably identify patients who do not require surgical re-exploration, and guide biopsies when they are indicated.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G and Canevari S (1997) Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med 38: 1378–1381
Colcher D, Esteban J and Carasquillo JA (1987) Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218–4224
Colombo P, Paganelli G, Magnani P, Songini C, Fazio F and Faglia G (1993) Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors. J Endocrinol Invest 16: 841–843
Copeland LJ, Vaccarello L and Lewandowski GS (1994) Second-look laparotomy in epithelial ovarian cancer. Obst Gynecol Clin North Am 21: 155–166
Cresman WT and Eddy GL (1989) Prognostic factors in relation to second look laparotomy in ovarian cancer. Ballières Clin Obstet Gynecol 3: 183–190
Crippa F, Buraggi GL, DiRe E, Gasparrini M, Seregni E, Canevari S, Gadina M, Presti M, Marini A and Seccamani E (1991) Radioimmunoscintigraphy of ovarian cancer with the MOv 18 monoclonal antibody. Eur J Cancer 27: 724–772
Dosio F, Magnani P, Paganelli G, Samuel A, Chiesa G and Fazio F (1994) Three-step tumor pre-targeting in lung cancer. J Nucl Biol Med 37: 228–233
Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards CL and Rutledge FN (1985) Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 55: 1129–1135
Grana C, Chinol M, Magnani P, Corti A, Sidoli A, Siccardi AG and Paganelli G (1996) In vivo tumor targeting based on the avidin–biotin system. Tumor Targeting 2: 230–239
Larson SM, Carrasquillo JA, Colcher DC, Yokoyama K, Reynolds JC and Bacharach SA (1991) Estimates of radiation absorbed dose for intraperitoneally administered Iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 32: 1661–1667
Lown RN, Carter WD, Saleh F and Sigeti JS (1995) Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy and CT. Radiology 195: 391–400
Magnani P, Paganelli G, Songini C, Samuel A, Sudati F, Siccardi AG and Fazio F (1996) Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer 74: 825–831
Matzku U, Kirchgessner H, Schmid U, Temponi M and Ferrone S (1989) Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med 30: 390–397
Method MW, Serafini AN, Averette HE, Rodriguez M, Penalver MA and Sevin B (1996) The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. Cancer 77: 2286–2293
Mezzanzanica D, Canevari S and Menard S (1988) Human ovarian carcinoma lysis by cytotoxic T-cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer 41: 609–615
Miotti S, Canevari S and Menard S (1987) Characterization of human ovarian carcinoma associated antigens defined by novel monoclonal antibodies with tumor restricted specificity. Int J Cancer 39: 297–303
Morgan MA, Noumoff JS, King S and Mikuta JJ (1992) A formula for predicting the risk of a positive second-look laparotomy in epithelial ovarian cancer: implications for a randomized trial. Obstet Gynecol 80: 944–948
Ozols RF, Rubin SC, Dembo A and Robboy SJ (1992) Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology, Hoskins WJ, Young R, Perez C (eds), pp. 731–781. Lippincott: Philadelphia
Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, Siccardi AG and Fazio F (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 51: 5960–5966
Paganelli G, Magnani P, Zito F, Lucignani G, Sudati F, Truci G, Motti E, Terreni M, Pollo B, Giovanelli M, Canal N, Scotti G, Comi G, Koch P, Maecke HR and Fazio F (1994) Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med 21: 314–321
Peltier P, Curtet C, Chatal JF, Le Doussal JM, Daniel G, Aillet G, Gruaz-Guyon A, Barbet J and Delaage M (1993) Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-Indium-DTPA and an Indium-111-labelled DTPA dimer. J Nucl Med 34: 1267–1273
Podratz KC and Kinney WK (1993) Second-look operation in ovarian cancer. Cancer 71: 1551–1558
Potter ME, Hatch KD and Soong SJ (1980) Second look laparotomy and salvage therapy: research modality only?. Gynecol Oncol 44: 3
Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB and Markman M (1991) Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum based chemotherapy. Gynecol Oncol 42: 137–141
Rubin SC (1993) Monoclonal antibodies in the management of ovarian carcinoma: a clinical perspective. Cancer 71: 1602–1612
Seccamani E, Tattanelli M, Mariani M, Spranzi E, Scassellati GA and Siccardi AG (1989) A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum sample. Nucl Med Biol 2: 167–170
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Magnani, P., Fazio, F., Grana, C. et al. Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy. Br J Cancer 82, 616–620 (2000). https://doi.org/10.1054/bjoc.1999.0972
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0972